Navigation Links
Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
Date:10/24/2011

SYDNEY, Oct. 24, 2011 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care."

Pharmaxis expects the European Commission to confirm this opinion and grant the Marketing Authorisation for Bronchitol in January 2012.

Pharmaxis CEO Dr Alan Robertson welcomed the decision saying, "This outcome from the CHMP meeting is an important milestone for the company.  It is good news for the cystic fibrosis (CF) community which has supported us throughout the development of Bronchitol.  As the life expectancy of CF patients has lengthened, the size of the adult population in Europe has increased.  Bronchitol will be used for CF patients aged 18 and above, which represents about two thirds of all patients who could potentially benefit from the drug. Pharmaxis will undertake a short term clinical trial in children (age 6-17) with a view to extending the license to this age group.

"Bronchitol is a drug which was discovered and developed in Australia.  It is approved for marketing in Australia and is now set to become available throughout the 27 countries of the European Union.  This outcome represents the culmination of a great deal of work by many people.

"Pharmaxis will move quickly to commercialise Bronchitol in Europe.  We have established our supply and logistics arrangements and advanced launch preparations and pricing applications with our marketing partner, Quintiles.  The awareness of Bronchitol's clinical data amongst CF clinicians has increased through publications and presentations at scientific conferences.  European clinicians provided valuable support to the CHMP decision and
'/>"/>

SOURCE Pharmaxis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
2. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
3. Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
4. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
7. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
8. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Pharmaxis Establishes Named Patient Program for Bronchitol
11. Pharmaxis Long-Term Safety Study of Bronchitol Completes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/rt3mhz/deciphering ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing Demands ... It has been publicly recognized that global ... series of challenges in the recent years. The ... in small molecule product manufacturing; increasingly challenging process ...
(Date:7/7/2015)... 7, 2015   Decision Resources Group ... dialysis patient management in the U.S. versus the ... U.S. and EU5 nephrologists from approximately 1,870 dialysis ... the most commonly used renal medications in dialysis ... considerably between the two regions.      Other ...
(Date:7/7/2015)... BANGALORE , July 7, 2015 ... innovative clinical trial data management solutions, has been featured ... publication named " EDC and eCOA / ePRO Market ... is one of the leading providers of research and ... 22 EDC and eCOA / ePRO tools in the ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
... Minimally Invasive Surgery Symposium (MISS) will include discussion of ... surgery, single-port bariatric surgery, transoral gastroplasty, and other "frontier" ... by MISS Executive Director Philip R Schauer, MD, on ... , The five-day CME conference, which will be held ...
... Oct. 27 Endologix, Inc. (Nasdaq: ... disorders, today announced financial results for the three and ... McDermott, Endologix President and Chief Executive Officer, said, "Our ... sales of new products by our domestic sales force ...
Cached Medicine Technology:Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego 2Endologix Reports 47% Third Quarter 2009 Revenue Growth 2Endologix Reports 47% Third Quarter 2009 Revenue Growth 3Endologix Reports 47% Third Quarter 2009 Revenue Growth 4Endologix Reports 47% Third Quarter 2009 Revenue Growth 5Endologix Reports 47% Third Quarter 2009 Revenue Growth 6Endologix Reports 47% Third Quarter 2009 Revenue Growth 7Endologix Reports 47% Third Quarter 2009 Revenue Growth 8
(Date:7/7/2015)... ... 07, 2015 , ... This week Northeast Nebraska Imaging, Norfolk’s ... The website’s goal is to provide patients with detailed information about the various ... appointments online. , Part of the center’s rebranding efforts, the website was designed ...
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers for Disease ... Massachusetts , and the Multicultural AIDS Coalition $3.78 million for a five-year ... sex with men (MSM) and transgender women, the groups at highest risk of ...
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's headquarters to ... is a state of the art building, located with easy access to New York ... said, "We are pleased to service our clients from such a premier location and ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... provider of advanced delivery technologies and development solutions for drugs, biologics and ... agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology ...
(Date:7/7/2015)... LINCOLN, R.I. (PRWEB) , ... July 07, 2015 , ... ... take the proper precautions, however, so Amica Insurance is sharing some safety tips. , ... activities, sports and gardening: , Leisure activities/sports, , Start slowly. ...
Breaking Medicine News(10 mins):Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2
... By Maryann Mott HealthDay Reporter , FRIDAY, March ... workers spent nearly 10 hours removing hundreds of sick and ... of the United States, larger animal-hoarding cases. More than ... and rabbits to dogs and cats -- had been living ...
... Most people want to take responsibility for their health but ... a new survey. The statewide poll of Pennsylvania adults ... believe they are more responsible for their personal health than ... and 2.3 percent didn,t know. The survey also found ...
... Approximately five percent of prescriptions submitted by CVS Caremark ... during 2009 included a "dispense as written" (DAW) designation. ... dispensing of a specific brand-name drug and not a ... to $7.7 billion annually, according to a new study ...
... for Cancer Research (AACR) announced today that Carey Anders, ... UNC Lineberger Comprehensive Cancer Center will receive a Breast ... The $181,000 grant will be presented at the ... Florida, April 2-6. The grant will fund laboratory ...
... (HealthDay News) -- A poor diet is associated with a ... study has found. Researchers analyzed data from 72,833 older ... more than a single nutrient were associated with a 21 ... with deficiencies in three nutrients. Women with anemia consumed ...
... ORLANDO, Fla. The American Association for Cancer Research ... will present three INNOVATOR Awards at the AACR 102nd ... Annual Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research ... assistant professor in the department of obstetrics, gynecology and ...
Cached Medicine News:Health News:Animal 'Hoarding' Often Tied to Mental Illness 2Health News:Animal 'Hoarding' Often Tied to Mental Illness 3Health News:Animal 'Hoarding' Often Tied to Mental Illness 4Health News:Research finds 'dispense as written' prescriptions may add $7.7 billion to annual health care costs 2Health News:UNC physician-scientist receives grant to study breast cancer brain metastases 2Health News:Poor Eating Habits May Lead to Anemia in Older Women 2Health News:AACR and Landon Foundation support the next generation of researchers with INNOVATOR Awards 2Health News:AACR and Landon Foundation support the next generation of researchers with INNOVATOR Awards 3Health News:AACR and Landon Foundation support the next generation of researchers with INNOVATOR Awards 4Health News:AACR and Landon Foundation support the next generation of researchers with INNOVATOR Awards 5
... The Stabilizing Ankle support features ... which lock the calcaneus into ... eversion and inversion. The full-circumference ... and stability. Ideal for chronic ...
... Wee Walker Pediatric Boot is ... pediatric boot that offers superior ... Only two sizes are offered ... sizes will fit left or ...
... Boot is designed as a flexible ... the mid-tibia or fibula to mid-foot ... support. The Bledsoe EZ Set PTB ... motion from 20 degrees of dorsi-flexion ...
... as a flexible and attractive alternative to casting ... and also for second and third degree ankle ... Bledsoe Hi-Top Boot but offers similar support. The ... range of motion from 20 degrees of dorsi-flexion ...
Medicine Products: